These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12937119)

  • 1. Haemolytic anaemia associated with high dose intravenous immunoglobulin therapy in a child with Guillain-Barré syndrome.
    Trifa M; Simon L; Hamza J; Bavoux F; des Roziers NB
    Arch Dis Child; 2003 Sep; 88(9):836-7. PubMed ID: 12937119
    [No Abstract]   [Full Text] [Related]  

  • 2. [Haemolytic anaemia as a complication to intravenous infusion of human immunoglobulin].
    Juel J; Markvardsen LH; Jakobsen J
    Ugeskr Laeger; 2011 Aug; 173(33):1963-4. PubMed ID: 21849136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barré syndrome.
    Rhee DY; Park GH; Chang SE; Lee MW; Choi JH; Moon KC; Koh JK
    J Eur Acad Dermatol Venereol; 2009 May; 23(5):602-4. PubMed ID: 18761548
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome.
    Abd-Allah SA; Jansen PW; Ashwal S; Perkin RM
    J Child Neurol; 1997 Sep; 12(6):376-80. PubMed ID: 9309521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2001; (2):CD002063. PubMed ID: 11406030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible association of Guillain-Barré syndrome and hepatitis A vaccination.
    Blumenthal D; Prais D; Bron-Harlev E; Amir J
    Pediatr Infect Dis J; 2004 Jun; 23(6):586-8. PubMed ID: 15194849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome.
    Diener HC; Haupt WF; Kloss TM; Rosenow F; Philipp T; Koeppen S; Vietorisz A;
    Eur Neurol; 2001; 46(2):107-9. PubMed ID: 11528165
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy.
    Byrne NP; Henry JC; Herrmann DN; Abdelhalim AN; Shrier DA; Francis CW; Powers JM
    Neurology; 2002 Aug; 59(3):458-61. PubMed ID: 12177388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; Doorn PA
    Cochrane Database Syst Rev; 2004; (1):CD002063. PubMed ID: 14973982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin high-dose therapy: RBC-alloantibodies in commercial preparations and haemolytic anaemia: a case report.
    Kluge A; Dopfer R; Pfeiffer-Wolf I; Roelcke D
    Beitr Infusionsther Transfusionsmed; 1994; 32():474-5. PubMed ID: 9422126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
    Misawa S
    Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras.
    Koul R; Chacko A; Ahmed R; Varghese T; Javed H; Al-Lamki Z
    J Child Neurol; 2003 Nov; 18(11):767-71. PubMed ID: 14696904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2006 Jan; (1):CD002063. PubMed ID: 16437439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of immunoglobulin in severe childhood Guillain-Barré syndrome.
    Ortiz-Corredor F; Peña-Preciado M
    Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splenic rupture associated with primary CMV infection, AMSAN, and IVIG.
    de Havenon A; Davis G; Hoesch R
    J Neuroimmunol; 2014 Jul; 272(1-2):103-5. PubMed ID: 24856574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2010 Jun; (6):CD002063. PubMed ID: 20556755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin for Guillain-Barré syndrome: how effective?
    Tasdemir HA; Dilber C; Kanber Y; Uysal S
    J Child Neurol; 2006 Nov; 21(11):972-4. PubMed ID: 17092465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse effects of intravenous human polyvalent immunoglobulins].
    Chapuis C; Guy N; Besson G
    Rev Neurol (Paris); 2008 Sep; 164 Spec No 3():F203-10. PubMed ID: 18992580
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Guillain-Barré syndrome.
    Winer JB
    QJM; 2002 Nov; 95(11):717-21. PubMed ID: 12391383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.